Romana Malik
Internal Medicine · New Castle, INNPI 1487948501
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AstraZeneca at 24.4% of the total. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Novo Nordisk$643
- GSK$331
- Bayer$297
- Pfizer$282
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,081100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $1,482 |
| AbbVie(2 entities) | 74 | $1,213 |
| Novo Nordisk | 27 | $643 |
| GSK | 20 | $331 |
| Bayer | 13 | $297 |
| Pfizer | 12 | $282 |
| Lilly USA, LLC | 13 | $207 |
| E.r. Squibb & Sons, L.L.C. | 5 | $163 |
| Johnson & Johnson | 5 | $136 |
| Novartis | 7 | $135 |
| Astellas Pharma US Inc | 7 | $132 |
| Teva Pharmaceuticals USA, Inc. | 1 | $117 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $109 |
| Noctrix Health, Inc. | 1 | $105 |
| Amgen | 5 | $93 |
| Alnylam Pharmaceuticals Inc. | 4 | $77 |
| Axsome Therapeutics, Inc. | 5 | $73 |
| Amarin Pharma, Inc. | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| Boehringer Ingelheim | 4 | $54 |
| Lundbeck LLC | 3 | $44 |
| Biogen | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 8 | $35 |
| Medtronic | 2 | $32 |
| Exact Sciences | 2 | $32 |
| Corium, LLC | 2 | $27 |
| Sanofi Pasteur Inc. | 2 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Covis Pharma GmbH | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Echosens North America, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$500
- VRAYLAR$370
- AIRSUPRA$237
- BREZTRI AEROSPHERE$125
- Kerendia$123
- RYBELSUS$122
- AREXVY$121
- ELIQUIS$121
- ProAir Digihaler$117
- AirDuo RespiClick$117
- ArmonAir Digihaler$117
- BREZTRI$116
- Wegovy$116
- CAMZYOS$110
- NIDRA$105
How this compares
$6,081 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 170 | $190,739 |
| OzempicSemaglutide | 69 | $102,454 |
| FarxigaDapagliflozin Propanediol | 89 | $80,909 |
| TrulicityDulaglutide | 26 | $51,992 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $32,089 |
| MounjaroTirzepatide | 21 | $30,436 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $24,302 |
| JanuviaSitagliptin Phosphate | 18 | $21,313 |
| EliquisApixaban | 17 | $19,618 |
| XareltoRivaroxaban | 21 | $19,129 |
| AptiomEslicarbazepine Acetate | 12 | $14,986 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $11,556 |
| Repatha SureclickEvolocumab | 16 | $9,920 |
| MyrbetriqMirabegron | 12 | $9,906 |
| TradjentaLinagliptin | 17 | $7,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $54 | $206,245201 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,482 | $117,649134 claims |
| Novo NordiskOzempic | $643 | $102,45469 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $207 | $82,42947 claims |
| GSKBreo Ellipta, Anoro Ellipta | $331 | $35,85861 claims |
| PfizerEliquis | $282 | $19,61817 claims |
| Johnson & JohnsonXarelto | $136 | $19,12921 claims |
| Astellas Pharma US IncMyrbetriq | $132 | $9,90612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in New Castle
- Gregory BojrabNew Castle$12K
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.